Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome
Information source: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Myelokathexis; WHIMS; Neutropenia; Warts
Intervention: Plerixafor (Drug); G-CSF (Drug)
Phase: Phase 3
Status: Recruiting
Sponsored by: National Institute of Allergy and Infectious Diseases (NIAID) Official(s) and/or principal investigator(s): David H McDermott, M.D., Principal Investigator, Affiliation: National Institute of Allergy and Infectious Diseases (NIAID)
Overall contact: Daniel Velez, R.N., Phone: (301) 594-1549, Email: velezds@mail.nih.gov
Summary
Background:
- WHIMS (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis Syndrome) is a rare
disease. It can cause cancers, infections, and warts. Researchers want to see if a drug
called plerixafor can treat WHIMS.
Objective:
- To compare plerixafor versus granulocyte colony stimulating factor (G-CSF) for preventing
infections in people with WHIMS.
Eligibility:
- People ages 10 75 with WHIMS who have a CXCR4 gene mutation.
Design:
- Participants will be screened with a medical history, physical exam, and blood and
urine tests. They may have heart and spleen tests and body scans. They may have samples
of skin or warts taken. Researchers may take photographs of warts.
- Participants will start twice daily self-injections of G-CSF. Their doctors will decide
the dosage.
- Initial Period (4 12 weeks)
- Participants will:
- continue the injections and their usual antibiotics and/or immunoglobulin
- have blood drawn
- keep a daily health diary
- Participants will visit the clinic for 2 days without injections.
- Adjustment Period 1 (8 weeks):
- Participants will:
- continue twice daily injections from home
- continue the daily health diary
- have blood tests every 2 weeks.
- Treatment Year 1:
- Participants will
- receive either plerixafor or G-CSF injections twice daily
- continue the health diary
- have blood tests every 2 months
- visit the clinic about every 4 months
- At the end of year 1, participants will visit the clinic for an evaluation. They will
switch to the other study drug. They will have an 8-week adjustment and 1-year
treatment period.
- At the end of year 2, participants will visit the clinic to complete their injections
and go back to their previous G-CSF regimen. Participants will continue their daily
health diary and have blood tests for 5 6 months.
Clinical Details
Official title: A Phase III Double-Blind Randomized Crossover Study of Plerixafor Versus G-CSF in the Treatment of Patients With WHIM Syndrome.
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Primary outcome: The primary endpoint is infection severity, which is measured as a composite of multiple weighted parameters according to rules defined in Appendix D of the protocol.
Secondary outcome: Component measures of infections; incidence and duration of infections, fevers, antibiotic treatments, and hospitalization.Control of warts as defined by at least a 50% reduction in numbers, areas or size of existing warts and number of new warts. Blood count and immunological parameters.
Detailed description:
Warts, hypogammaglobulinemia, infections, and myelokathexis syndrome (WHIMS) is a rare
combined primary immunodeficiency disorder caused by gain-of-function mutations in the gene
for the chemokine receptor CXCR4. Normally, CXCR4 is expressed on most leukocyte subsets and
functions in part to promote hematopoietic stem cell (HSC) and neutrophil homing to and
retention in bone marrow. WHIM mutations alter the CXCR4 carboxyl terminus, which enhances
and prolongs receptor signaling. As a result, egress of normally produced and functional
neutrophils from the bone marrow to the blood is impaired causing neutropenia, a bone marrow
pathologic finding referred to as myelokathexis. A similar mechanism may also affect other
leukocyte subsets since WHIM patients usually are panleukopenic. Consequently, WHIM patients
are predisposed to frequent acute bacterial infections, especially in the sinopulmonary
tract, that may cause chronic morbidity, respiratory insufficiency and in some cases
premature death. WHIM patients also have marked difficulty clearing infections with Human
Papillomavirus (HPV), resulting in persistent cutaneous and anogenital warts that in several
reported cases have evolved into cancer. Several deaths have also occurred due to cancer
associated with Epstein - Barr virus (EBV) infection. Therapies currently used for WHIMS are
non-specific and expensive, and include Granulocyte Colony-Stimulating Factor (G-CSF) (the
drug currently approved by the Food and Drug Administration (FDA) to treat severe congenital
neutropenia), intravenous immunoglobulin (IVIg), and prophylactic antibiotics. None of these
measures has been formally evaluated for efficacy in WHIM syndrome (WHIMS); however, in our
clinical experience based on the treatment of 24 WHIM patients seen at the National
Institutes of Health (NIH) since 2006, recurrent bacterial infections continue to occur,
despite the fact that the absolute neutrophil count (ANC) can be readily maintained above
500 cells/microliter by G-CSF and IgG levels can be restored to the normal range by IVIg.
Thus, there continues to be a major unmet medical need for effective therapy in WHIMS
despite the availability and application of best therapy for neutropenia and
hypogammaglobulinemia in these patients. Plerixafor (Mozobil ) is a specific small
molecule antagonist of CXCR4, licensed by the FDA for HSC mobilization for transplantation
in cancer, and is therefore a logical candidate for molecularly targeted treatment of WHIMS.
The goal of treatment would be to reduce CXCR4 signaling to normal, not to zero, thus,
absent any off-target effects, targeted chronic treatment with this agent may be safe. In
this regard, 2 recent short term Phase I dose-escalation studies of plerixafor, one from our
group, in a total of 9 patients demonstrated that the drug could safely mobilize not only
neutrophils, but also all other leukocyte subsets that are decreased in the blood of WHIM
patients. A follow-up Phase I study, conducted by our group, in 3 patients given plerixafor
0. 02-0. 04 mg/kg/d for 6 months demonstrated that these hematopoietic effects were durable.
Moreover, the frequency of infection was reduced on plerixafor as compared to retrospective
data mined for the three years before starting therapy and prospective data collected for
one year after ending therapy, even though 2 of the patients were taking GCSF during the
comparison time periods. No new warts occurred during treatment and several existing warts
improved or resolved. Although these results are encouraging, the small number of patients
studied, limited duration of drug treatment, and retrospective mining of control data leave
open to question whether plerixafor is truly efficacious for clinical outcomes in WHIMS. The
randomized, double blinded, crossover trial described here is designed to answer this
question by establishing the long-term safety and clinical efficacy (primary endpoint:
infection severity; multiple secondary endpoints including wart control) of plerixafor as
compared to G-CSF in the treatment of WHIMS patients 10-75 years of age. G-CSF as a
comparator is required because of its approved use in patients with severe congenital
neutropenia (SCN).
Brief outline of study we intend to randomize 20 patients and treat them in a
double-blinded manner for 1 year with G-CSF and 1 year with plerixafor using a crossover
design to allow direct comparison of infection severity during treatment with both agents,
at doses determined by the patient s individual neutrophil response. A schedule of events
has been provided in Appendix A. Data will be analyzed as specified in the Statistics
section (Section 14) after randomization. Tolerability and patient drug preference will also
be assessed.
Eligibility
Minimum age: 10 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
- INCLUSION CRITERIA:
Subjects are eligible to enter the study if they meet all of the following criteria:
1. Age greater than or equal to 10 and less than or equal to 75 years.
2. Heterozygous mutation in the C-tail of CXCR4 in addition to a clinical diagnosis of
WHIMS.
3. Documented neutropenia with a baseline ANC below 1500 cells/microL of blood.
4. History of severe and/or recurrent infections.
5. Willingness to interrupt G-CSF medication, 2 days prior to study drug injection.
6. Must have a local medical provider for medical management.
7. Must be willing to provide blood, plasma, serum, and DNA samples for storage.
8. Women of childbearing potential must agree to take appropriate steps to avoid
becoming pregnant for the duration of the study. Participants in whom pregnancy is
biologically possible must use at least 2 study approved methods of contraception,
one of which must be a barrier method, and must continue contraception until 5 months
after stopping the study drug:
- Male or female condoms with a spermicide,
- Diaphragm or cervical cap with spermicide,
- Intrauterine device,
- Contraceptive pills or patch, Norplant, Depo-Provera or other FDA-approved
contraceptive,
- Male partner with vasectomy and documented aspermatogenic sterility.
9. Willingness to comply with the study medications, visits, and procedures, as deemed
necessary by the principal investigator (PI).
EXCLUSION CRITERIA:
If any of the following exclusion criteria are met, a subject will not be enrolled in this
study:
1. Neutropenia due to maturation defects in the myeloid lineage or a type of
neutropenia, which in the investigator s opinion, is unlikely to improve from the
medication administered in this study.
2. Pregnant or breast-feeding women.
3. Known hypersensitivity to plerixafor, G-CSF, or any components of the products.
4. Predisposition to or history of life-threatening cardiac arrhythmia.
5. Requiring dialysis or having markedly impaired renal function with a Creatinine
Clearance (CrCl) < 15 mL/min.
6. Condition that in the investigator s opinion places a subject at undue risk by
participating in the study.
Locations and Contacts
Daniel Velez, R.N., Phone: (301) 594-1549, Email: velezds@mail.nih.gov
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland 20892, United States; Recruiting For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL), Phone: 800-411-1222, Ext: TTY8664111010, Email: prpl@mail.cc.nih.gov
Additional Information
NIH Clinical Center Detailed Web Page
Related publications: McDermott DH, Liu Q, Velez D, Lopez L, Anaya-O'Brien S, Ulrick J, Kwatemaa N, Starling J, Fleisher TA, Priel DA, Merideth MA, Giuntoli RL, Evbuomwan MO, Littel P, Marquesen MM, Hilligoss D, DeCastro R, Grimes GJ, Hwang ST, Pittaluga S, Calvo KR, Stratton P, Cowen EW, Kuhns DB, Malech HL, Murphy PM. A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor. Blood. 2014 Apr 10;123(15):2308-16. doi: 10.1182/blood-2013-09-527226. Epub 2014 Feb 12. McDermott DH, Liu Q, Ulrick J, Kwatemaa N, Anaya-O'Brien S, Penzak SR, Filho JO, Priel DA, Kelly C, Garofalo M, Littel P, Marquesen MM, Hilligoss D, Decastro R, Fleisher TA, Kuhns DB, Malech HL, Murphy PM. The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome. Blood. 2011 Nov 3;118(18):4957-62. doi: 10.1182/blood-2011-07-368084. Epub 2011 Sep 2. McDermott DH, Lopez J, Deng F, Liu Q, Ojode T, Chen H, Ulrick J, Kwatemaa N, Kelly C, Anaya-O'Brien S, Garofalo M, Marquesen M, Hilligoss D, DeCastro R, Malech HL, Murphy PM. AMD3100 is a potent antagonist at CXCR4(R334X) , a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome. J Cell Mol Med. 2011 Oct;15(10):2071-81. doi: 10.1111/j.1582-4934.2010.01210.x.
Starting date: August 2014
Last updated: August 18, 2015
|